Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
Novozymes and Chr. Hansen Complete Merger, Forming Novonesis
In a significant development in the biosolutions sector, Novozymes A/S and Chr. Hansen Holding A/S successfully completed their merger, forming a new...
Obesity: Arecor Therapeutics partners with TRx Biosciences
The collaboration of the biopharma and drug discovery specialists targets a potential US$80bn market of obesity drugs, according to Bloomberg...
Unitaid awards Medincell US$6m to fight malaria
The funding commitment for MedinCell Corp’es reformulation of the antipararsitic ivermectin comes after great progress in malaria vaccines: The...
Bioplastics production capacity to quadruple by 2028
Global production capacity for bioplastics will almost quadruple within the next five years, according to estimates of the Nova Institute on behalf...
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...